welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Mayo Clinic Researcher Finds Potential Target to Control Rare Genetic Disease That Strikes in Teen Years
A new study from researchers at Mayo Clinic Center for Individualized Medicine, described in the New England Journal of Medicine, reveals patients with the most severe FAP disease may benefit from a novel combination therapy. The study points to a possible target for intervention and prevention.
Author Niloy Jewel (Jewel) Samadder, M.D., a gastroenterologist and cancer genetics expert at Mayo Clinic’s campus in Ariz., and his colleagues, studied 171 patients with FAP who had various disease stages, at 20 centers in the U.S., Canada and Europe. Researchers evaluated the benefit and safety of the combination of eflornithine and sulindac compared to each drug alone. The investigation represents the largest international phase III FAP trial to date involving pharmaco-prevention — the use of a medication to prevent the need for surgery or other disease progression.
expertly curated content related to this topic
-
Education and Management of Patients with Familial Adenomatous Polyposis. Are We Making Progress? A Case ReportAbstract: A 25-year-old male patient was...
-
Surgical Prophylaxis in Familial Adenomatous Polyposis: Do Pre-Existing Desmoids Outside the Abdominal Cavity Matter...Desmoid tumours (DT) are myofibroblastic...
-
Surveillance of Duodenal Polyposis in Familial Adenomatous Polyposis: Should the Spigelman Score Be Modified?BACKGROUND: Duodenal polyposis is a mani...
-
Pouch-Anal Anastomosis vs Straight Ileoanal Anastomosis in Pediatric Patients: A Meta-AnalysisBACKGROUND : Restorative proctocolectomy...
-
Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
-
Familial Colon Cancer Syndromes: An Update of a Rapidly Evolving FieldColorectal cancer (CRC) is a major cause...
-
Ostomy Tips And TricksThere is a pretty steep learning curve f...